GSHD:NASDAQGoosehead Insurance, Inc. Analysis
Data as of 2026-04-07 - not real-time
$44.49
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Goosehead Insurance (GSHD) is trading at $44.49, comfortably above its DCF‑derived fair value of $26.44, indicating a significant premium. The stock sits just above its 20‑day SMA ($43.52) but remains well under the 50‑day ($50.65) and 200‑day ($72.73) averages, underscoring a bearish medium‑term trend. Technical signals are mixed: RSI is neutral at 46, the MACD histogram is positive (bullish) while the overall trend is classified as bearish and volume is on a decreasing trajectory, suggesting weakening momentum. Volatility is high at 56.7% over the past 30 days and beta (0.74) points to modest market sensitivity, yet the recent price action reflects heightened risk.
Fundamentally, the company posted 12.2% revenue growth and maintains a solid operating margin (29.3%) with strong cash generation (operating cash flow $91.8M). Forward EPS is projected at $2.66, compressing the forward P/E to 16.7, closer to the industry average (16.7). However, the balance sheet shows a large debt load ($352M) against negligible equity (negative book value per share), and the PE of 42.8 versus the sector’s 16.7 signals overvaluation. Recent material news includes a new General Counsel appointment, RBC Capital’s initiation of coverage with a "Sector Perform" rating, and management’s discussion of buybacks to fund tech‑driven growth, all of which could influence investor sentiment.
Fundamentally, the company posted 12.2% revenue growth and maintains a solid operating margin (29.3%) with strong cash generation (operating cash flow $91.8M). Forward EPS is projected at $2.66, compressing the forward P/E to 16.7, closer to the industry average (16.7). However, the balance sheet shows a large debt load ($352M) against negligible equity (negative book value per share), and the PE of 42.8 versus the sector’s 16.7 signals overvaluation. Recent material news includes a new General Counsel appointment, RBC Capital’s initiation of coverage with a "Sector Perform" rating, and management’s discussion of buybacks to fund tech‑driven growth, all of which could influence investor sentiment.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Price trading above 20‑day SMA but below longer‑term averages
- Decreasing volume and high 30‑day volatility
- Current price far exceeds DCF fair value, indicating overvaluation
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Revenue growth of 12% and strong operating margins
- Forward P/E compressing toward industry norms
- Persistent bearish technical trend and elevated debt levels
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Sustained cash generation and positive earnings outlook
- Strategic buyback program and tech‑driven growth initiatives
- Negative book value and high historical drawdown limiting upside
Key Metrics & Analysis
Financial Health
Revenue Growth12.20%
Profit Margin7.63%
P/E Ratio42.8
ROA12.07%
P/B Ratio-11.5
Op. Cash Flow$91.8M
Free Cash Flow$57.3M
Industry P/E16.7
Technical Analysis
TrendBearish
RSI46.2
Support$40.00
Resistance$49.65
MA 20$43.52
MA 50$50.65
MA 200$72.73
MACDBullish
VolumeDecreasing
Fear & Greed Index76.5
Valuation
Fair Value$26.44
Target Price$73.00
Upside/Downside64.08%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.74
Volatility56.75%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.